Articles | Volume 8, issue 6
https://doi.org/10.5194/jbji-8-219-2023
https://doi.org/10.5194/jbji-8-219-2023
Original full-length article
 | 
30 Oct 2023
Original full-length article |  | 30 Oct 2023

Antimicrobial prophylaxis with teicoplanin plus gentamicin in primary total joint arthroplasty

Tariq Azamgarhi, Craig Gerrand, John A. Skinner, Alexander Sell, Robert A. McCulloch, and Simon Warren

Viewed

Total article views: 1,274 (including HTML, PDF, and XML)
HTML PDF XML Total BibTeX EndNote
930 240 104 1,274 90 113
  • HTML: 930
  • PDF: 240
  • XML: 104
  • Total: 1,274
  • BibTeX: 90
  • EndNote: 113
Views and downloads (calculated since 30 Oct 2023)
Cumulative views and downloads (calculated since 30 Oct 2023)

Viewed (geographical distribution)

Total article views: 1,240 (including HTML, PDF, and XML) Thereof 1,240 with geography defined and 0 with unknown origin.
Country # Views %
  • 1
1
 
 
 
 

Cited

Latest update: 08 Oct 2025
Download
Short summary
We compared prosthetic joint infection (PJI) and acute kidney injury (AKI) rates among cohorts before and after changing our hospital's antimicrobial prophylaxis from cefuroxime to teicoplanin plus gentamicin for primary total joint arthroplasty. Switching to teicoplanin and gentamicin was associated with a significant risk reduction for PJI of 75.2 %. Significantly higher AKI rates were seen in patients receiving teicoplanin plus gentamicin; however, these were mild (KDIGO stage 1).
Share